Clinical Research Directory
Browse clinical research sites, groups, and studies.
Trilaciclib Prevents Myelosuppression With Chemoradiotherapy
Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Summary
To evaluate the protective effect of Trilaciclib on myelosuppression in patients with limited-stage small cell lung cancer associated with concurrent chemoradiotherapy and discuss the effect of gut microbiota changes on myelosuppression
Official title: To Evaluate the Protective Effect of Trilaciclib on Myelosuppression in Patients With Limited-stage Small Cell Lung Cancer Associated With Concurrent Chemoradiotherapy and Discuss the Effect of Gut Microbiota Changes on Myelosuppression
Key Details
Gender
All
Age Range
40 Years - Any
Study Type
INTERVENTIONAL
Enrollment
40
Start Date
2024-06-26
Completion Date
2026-06-30
Last Updated
2024-09-24
Healthy Volunteers
No
Conditions
Interventions
Trilaciclib
During concurrent chemoradiotherapy in limited-stage small cell lung cancer, Trilaciclib is administered prophylactically before the first cycle of chemotherapy
Locations (1)
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China